Dr. Hulihan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
201 N Congress St
Newtown, PA 18940Phone+1 215-497-7472- Is this information wrong?
Education & Training
- Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1987 - 1990
- Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1986 - 1987
- Drexel University College of MedicineClass of 1986
Certifications & Licensure
- PA State Medical License 1988 - 2022
- MN State Medical License 1990 - 1991
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 25 citationsAssociation Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus.Elan L. Guterman, John P. Betjemann, Aimetti Alex, Justin W Li, Zheng Wang, David Yin, Hulihan Joseph, Thomas S. Lyons, Gavin Miyasato, Adam Strzelczyk> ;JAMA Neurology. 2021 May 1
- 20 citationsPaliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsLarry Alphs, Cynthia A. Bossie, Jennifer Kern Sliwa, Dong-Jing Fu, Yi-Wen Ma, Joseph Hulihan> ;Neuropsychiatric Disease and Treatment. 2013 Mar 5
- 3 citationsCost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.Larry Alphs, William H. Olson, Ibrahim Turkoz, John Fastenau, Joseph Hulihan> ;The Journal of Clinical Psychiatry. 2012 Oct 15
- Join now to see all
Press Mentions
- Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateAugust 3rd, 2021
- Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceJanuary 6th, 2021
- Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)July 30th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: